CG
ALXN

Clinton Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Clinton Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,891
Closed -$322K – 513
2018
Q1 		$322K Buy
+2,891
New +$346K 0.03% 302
2017
Q4 		– Sell
-1,812
Closed -$254K – 539
2017
Q3 		$254K Buy
+1,812
New +$246K 0.03% 340
2016
Q4 		– Sell
-10,818
Closed -$1.33M – 1066
2016
Q3 		$1.33M Sell
10,818
-50,861
-82% -$6.55M 0.06% 388
2016
Q2 		$7.2M Buy
+61,679
New +$8.75M 0.32% 84
2015
Q2 		– Sell
-9,459
Closed -$1.64M – 740
2015
Q1 		$1.64M Buy
+9,459
New +$1.71M 0.43% 57
2014
Q3 		– Sell
-8,977
Closed -$1.4M – 509
2014
Q2 		$1.4M Buy
8,977
+5,072
+130% +$801K 0.7% 24
2014
Q1 		$594K Buy
+3,905
New +$621K 0.23% 142

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $431B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return